SAB Biotherapeutics, Inc 8-K, filed Jun 18, 2026
SAB Biotherapeutics, Inc. (SABS)
About this 8-K
SAB Biotherapeutics, Inc filed this 8-K on June 18, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
|||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 18, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares of common stock entitled to vote at the Annual Meeting was 77,966,409, and there were 59,349,534 shares present in person or by proxy at the Annual Meeting, which represented approximately 76.12% of the outstanding shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction of business.
At the Annual Meeting, the shareholders voted to:
The voting results on these proposals were as follows:
Proposal 1: Election of four Class II directors
Director |
|
Votes For |
|
Withheld |
|
Broker Non-Votes |
|
David Zaccardelli, Pharm.D. |
|
48,352,114 |
|
2,984 |
|
10,994,436 |
|
David Link, MBA |
|
44,083,923 |
|
4,271,175 |
|
10,994,436 |
|
Katie Ellias |
|
48,350,086 |
|
5,012 |
|
10,994,436 |
|
Andrew Moin |
|
44,157,704 |
|
4,197,394 |
|
10,994,436 |
|
Proposal 2: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026
Votes For |
|
Votes Against |
|
Abstentions |
|
59,319,363 |
|
3,373 |
|
26,798 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
SAB Biotherapeutics, Inc. |
|
|
|
|
Date: |
June 18, 2026 |
By: |
/s/ Samuel J. Reich |
|
|
|
Samuel J. Reich |